Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGLS8429 (Farabursen) in patients with ADPKD
NCT05521191Phase 1Completed
- Sponsor
- Regulus Therapeutics
- Start
- Oct 2022
- Primary completion
- Jan 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of farabursen in autosomal dominant polycystic kidney disease (ADPKD) (3 arms), sponsored by Regulus Therapeutics. Primary endpoints: Incidence of Adverse Events at Day 113 and Impact of RGLS8429 on ADPKD biomarkers at Day 113. Started Oct 2022; status: completed.
02
Drugs
farabursen
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT05521191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521191.